Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies

Table 1

Summary of clinical trials and approved antiangiogenic therapies in hemato-lymphoid malignancies.

Drug class	Target	Study entities	Approved for
Anti-VEGF strategies
Bevacizumab (Avastin)	VEGF-A	AML, MDS, CLL, CML, NHL, MM	Metastatic colorectal cancer, NSCLC, breast cancer
RTK inhibitors
Vatalanib	VEGFR1-3, PDGFRβ, CD117	AML, PMF, MDS, CML, DLBCL, MM
Cediranib (Recentin)	VEGFR1-3, PDGFRβ, CD117	AML, MDS, CLL
Immunomodulators
Thalidomide		AML, MDS, MPN, CLL, NHL, MM	MM
Lenalidomide (Revlimid)		AML, MDS, CLL, NHL	MM, 5q-MDS